Conversely, if flecainide’s primary action in CPVT involves a direct effect on RyR2, it may be possible to identify a flecainide-like drug with similar or greater effect on RyR2, but much less influence on Nav1.5. Here, SCN5A is linked to catecholaminergic polymorphic ventricular tachycardia.